Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
I-MED Pharma is a privately held Canadian pharmaceutical company specializing in the diagnosis and management of ocular surface diseases, particularly dry eye disease (DED). Founded in 1989 and headquartered in Montreal, the company provides a comprehensive range of solutions including diagnostic tools, ocular hygiene products, and advanced tear film substitutes. Their flagship product lines, such as I-DROP and I-LID 'N LASH, are widely utilized by eye care professionals globally to treat conditions like Meibomian Gland Dysfunction (MGD) and blepharitis. I-MED Pharma is recognized for its commitment to research and development in ophthalmology, focusing on innovative viscoadaptive formulations that enhance patient comfort and clinical outcomes.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on IMED.